NCT02974751 (OPEN WATER) is a clinical trial of Aquablation in BPH, sponsored by PROCEPT BioRobotics.

Who is sponsoring NCT02974751?

NCT02974751 is sponsored by PROCEPT BioRobotics.

What drugs are being tested in NCT02974751?

Interventions in NCT02974751: Aquablation.

Is NCT02974751 still recruiting?

NCT02974751 is currently status unknown. Last updated 22 October 2019.

Last reviewed 2019-10-22 · How we verify

NCT02974751: OPEN WATER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue

Status unknown Last updated 22 October 2019

What this trial tests

trial testing Aquablation in BPH in 178 participants. Status unknown.

Timeline

5 September 2017

Primary endpoint
24 May 2019

29 February 2020

Quick facts

Lead sponsor	PROCEPT BioRobotics
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	178
Start date	5 September 2017
Primary completion	24 May 2019
Estimated completion	29 February 2020
Sites	5 locations across New Zealand, United Kingdom, Germany, Australia, Lebanon

Drugs / interventions tested

Aquablation

Conditions studied

BPH — all drugs for BPH →

Sponsor

PROCEPT BioRobotics — full company profile →

Who can join

Eligibility, male only, with BPH. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy of the AQUABEAM System for the treatment of Lower Urinary Tract Symptoms (LUTS) resulting from Benign Prostatic Hyperplasia (BPH).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Transfusion rates after 800 Aquablation procedures using various haemostasis methods.
Elterman D, Bach T, Rijo E, Misrai V, et al · · 2020 · cited 29× · PMID 31901210 · DOI 10.1111/bju.14990
First Multi-Center All-Comers Study for the Aquablation Procedure.
Bach T, Gilling P, El Hajj A, Anderson P, et al · · 2020 · cited 23× · PMID 32102329 · DOI 10.3390/jcm9020603
Aquablation: a novel and minimally invasive surgery for benign prostate enlargement.
Taktak S, Jones P, Haq A, Rai BP, et al · · 2018 · cited 20× · PMID 29899759 · DOI 10.1177/1756287218760518
Meta-analysis with individual data of functional outcomes following Aquablation for lower urinary tract symptoms due to BPH in various prostate anatomies.
Elterman D, Gilling P, Roehrborn C, Barber N, et al · · 2021 · cited 9× · PMID 35047807 · DOI 10.1136/bmjsit-2021-000090
Aquablation for benign prostatic hyperplasia: real-world prostate size relevance and bleeding events across 6 years.
Bitar M, Ferreira R, Shprits S, Buksh O, et al · · 2026 · cited 2× · PMID 41399106 · DOI 10.1111/bju.70118
Ejaculatory function after robotic waterjet ablation for the treatment of benign prostatic hyperplasia: a systematic review.
Bettencourt A, Wu J, Borrell JA, Furtado TP, et al · · 2026 · cited 1× · PMID 40369187 · DOI 10.1038/s41443-025-01087-6
Poster Session 2: Endourology, BPH (Part 1) : Sunday, June 30, 2024 • 16:10–17:40
Parkhomenko E, Farcas M, Pace K, Ordon M, et al · · 2024
NSAUA 2024 Annual Meeting Abstracts – Endourology, Stones
Ramadhan M, Braga A, Alzaid M, Benzouak T, et al · · 2024

Verify or expand the search:

Other trials of Aquablation

Trials testing the same drug.

NCT05169892 — Aquablation in Benign Prostatic Hyperplasia in Canada · recruiting
NCT03938194 — Waterjet Prostate Ablation · NA · terminated
NCT03123250 — Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II · NA · completed

Other recruiting trials for BPH

Currently open trials in the same condition.

NCT07115147 — Blue Diode Laser Vaporization for BPH · NA · recruiting
NCT05401032 — Proof-of-concept Study to Evaluate the Safety and Efficacy of Tryptophan in Patients with BPH. · Phase 2 · recruiting
NCT05719220 — Effect of Group Preoperative Pelvic Floor Training for HoLEP · recruiting
NCT05620784 — Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP · Phase 3 · recruiting
NCT05330520 — Long Term Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Pat · NA · recruiting

Other PROCEPT BioRobotics trials

Trials by the same sponsor.

NCT03191734 — French Aquablation Clinical Investigation Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue · NA · completed
NCT03123250 — Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II · NA · completed
NCT04308070 — Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia III · NA · completed
NCT03125889 — Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia II · NA · completed
NCT03125863 — Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02974751 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by PROCEPT BioRobotics
Last refreshed: 22 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02974751.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing